haijun_dong

DIA appoints Dr Haijun Dong as MD for DIA China

pharmafile | April 10, 2014 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing dia 

Biopharmaceutical executive Dr Haijun (Lou) Dong has been named as the new managing director for DIA China.

“Dr Dong brings considerable experience and expertise to DIA, with breadth and depth in the biopharmaceutical industry as well as in academia, and will continue to catalyse DIA’s presence and impact in China,” says DIA global chief executive Barbara Kunz.

Dr Dong previously held executive positions as chief executive for Lilly China Research and Development., a subsidiary of Eli Lilly and Company, and was president and chief executive of IMPACT Therapeutics, Inc.

Advertisement

Dr Dong has been employed by Roche in China and the US and other Chinese and international companies, serving in R&D, sales and marketing, business development and executive leadership capacities.

He holds an MBA from the China Europe International Business School and a doctorate in chemistry from the University of Washington—building on his undergraduate training as a chemist.

He brings a broad range of experience and expertise in the biopharmaceutical industry and academia to DIA, and will continue to grow DIA’s presence and impact in China.

Related Content

dia_logo

DIA Value, Access, and Regulatory Conference 2018

Dr Solange Corriol-Rohou, Senior Director, Global Regulatory Affairs & Policy, Europe, at AstraZeneca Global Medicines …

dialogo

DIA: Pharmacovigilance conference

We are in the midst of a breath-taking series of changes in the world of …

The Gateway to Local Adoption Series

Latest content